Drug firm Lilly makes largest investment in its home state

Indiana-based Eli Lilly is making the single biggest U.S. investment in synthetic medicine manufacturing at a new state business park in Lebanon, Ind.

The campus will comprise 600 acres and begin production in 2026, “scaling up” through 2028, according to a company release. The corporation declined further comment. The investment will expand Lilly’s ability to manufacture active pharmaceutical ingredients for Zepbound injection and Mounjaro injection. These drugs are for adults with chronic diseases like obesity and Type 2 diabetes.Not only is this the largest investment in synthetic drug manufacturing but it’s Lilly’s largest investment ever.

Indiana Gov. Eric Holcomb said the state attributes the investment to its “leadership” in developing sites like the LEAP Research and Innovation District.

Finance Finance Latest News, Finance Finance Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Eli Lilly’s Obesity Drug Crunch Shows Signs of Easing in JapanEli Lilly & Co.’s hefty investment in expanding production capacity for its popular weight-loss and diabetes drugs is starting to pay off in Japan, allowing the company to lift shipment controls it imposed in the country last year.
Source: BNNBloomberg - 🏆 83. / 50 Read more »